TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Tracon Pharmaceuticals Inc.
Study ID
NCT02396511
Phase
PHASE2
Status
Completed

Conditions

  • Choriocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TRC105 — BIOLOGICAL
    weekly i.v. TRC105 in combination with every 2 weeks i.v.bevacizumab, until progression or unacceptable toxicity develops
  • Bevacizumab — BIOLOGICAL
    Every 2 weeks i.v.bevacizumab in combination with weekly i.v. TRC105, until progression or unacceptable toxicity develops

Study Details

The purpose of this study is to determine whether TRC105 in combination with Bevacizumab is effective in the treatment of two patients with metastatic and refractory choriocarcinoma.

Key Dates

First listed
Mar 24, 2015
Start date
Jan 31, 2015
Status verified
May 2019
Primary completion
Dec 31, 2017
Completion
Dec 31, 2017

Study Design

Enrollment
2 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TRC105 and Bevacizumab
    TRC105 weekly intravenous infusion bevacizumab every 2 weeks intravenous infusion

Primary Outcome Measure

Progression Free Survival of Two Patients With Metastatic and Refractory Choriocarcinoma [ Time Frame: Assessed every 8 weeks for up to 35 Months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Dana-Farber Cancer InsititueBostonMassachusetts02215-

Find similar trials in Boston, MA

By research site
Dana-Farber Cancer Insititue· Boston, MA

Related Studies